Another group looked at gene expression levels of MECOM, ERG, WT1, GATA2, BAALC, MEIS1 and SPI1 in the bone marrow of 560 newly diagnosed AML patients and found that lower expression of MECOM and MEIS1 correlated with better CR rates, OS, and disease-free survival (DFS) [91]. This evidence concerns the gene MEIS1 and acute myeloid leukemia.